REVIEW ARTICLE
Year : 2020 | Volume
: 11 | Issue : 6 | Page : 890--894
Understanding superiority, noninferiority, and equivalence for clinical trials
Kamal Kishore1, Rahul Mahajan2
1 Department of Biostatistics, Postgraduate Institute of Medical Education and Research, Chandigarh, India
2 Department of Dermatology, Venereology, and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Correspondence Address:
Rahul Mahajan
Associate Professor, Department of Dermatology, Venereology, and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh - 160 012
India
Randomized control trialsare the gold standard for testing the efficacy of new interventions. Historically, superiority trials were methods of choice as reference (standard) interventions were not established for many disease conditions. However currently, reference interventions are available for most of adverse conditions. Despite this, many investigators are using superiority trials in comparison to more suitable noninferiority and equivalence trials. The application of noninferiority and equivalence trials is on the rise, but by and large, these trials are poorly understood, ill-conceived, inappropriately analyzed, and reported and misinterpreted.
How to cite this article:
Kishore K, Mahajan R. Understanding superiority, noninferiority, and equivalence for clinical trials.Indian Dermatol Online J 2020;11:890-894
|
How to cite this URL:
Kishore K, Mahajan R. Understanding superiority, noninferiority, and equivalence for clinical trials. Indian Dermatol Online J [serial online] 2020 [cited 2021 Jan 27 ];11:890-894
Available from: https://www.idoj.in/article.asp?issn=2229-5178;year=2020;volume=11;issue=6;spage=890;epage=894;aulast=Kishore;type=0 |
|
|
|
